Dextran gel, gum (Exopolysaccharide) : The Bacterial Polysaccharide, Master of Volume Expansion & Molecular Medicine

Dextran

The versatile, high-molecular-weight polysaccharide synthesized by benevolent bacteria, a remarkable example of nature's chemistry harnessed for human medicine. This complex glucose polymer, with its unique alpha-1,6 glycosidic linkages, has served as a life-saving plasma volume expander on battlefields and in operating rooms for decades. Beyond its classical role in transfusion medicine, dextran has evolved into a sophisticated biomedical platform, functioning as an antithrombotic agent, an ophthalmic lubricant, a drug delivery vehicle, and a foundational material for advanced wound care and nanomedicine. Its story is one of molecular adaptation, where subtle variations in chain length unlock a diverse array of clinical applications.

1. Overview:

Dextran is a complex branched polysaccharide composed exclusively of D-glucose units linked predominantly by alpha-1,6 glycosidic bonds, with occasional alpha-1,3, alpha-1,4, or alpha-1,2 branching points. It is not a single compound but a family of polymers with varying molecular weights, typically ranging from 1,000 to 2,000,000 Daltons, each with distinct physicochemical and biological properties. Its primary actions are determined by its molecular size. As a colloid, high-molecular-weight dextran (dextran 70, 70 kDa) exerts significant oncotic pressure, expanding plasma volume by drawing fluid from the interstitial space into the vascular compartment. Low-molecular-weight dextran (dextran 40, 40 kDa) improves microcirculatory flow by reducing blood viscosity and inhibiting erythrocyte aggregation. Across all molecular weights, dextran exhibits antithrombotic effects by coating platelets, erythrocytes, and the vascular endothelium, reducing their adhesiveness and aggregation. In ophthalmic preparations, it increases solution viscosity, prolonging contact time with the ocular surface to relieve irritation. In modern biomedical research, dextran serves as a versatile scaffold for hydrogels, drug conjugates, and nanomedicines, where its biocompatibility, biodegradability, and modifiable hydroxyl groups enable precise engineering for targeted therapies.

2. Origin and Common Forms:

Dextran is not found in plants or animals but is produced extracellularly by specific lactic acid bacteria when cultivated on sucrose-rich media. This bacterial origin is fundamental to its production and properties.

· Native Dextran (High Molecular Weight): The crude polysaccharide produced directly by bacterial fermentation, with molecular weights often exceeding several million Daltons. This form is too large for direct clinical use and requires controlled partial hydrolysis to reduce its size.

· Clinical Dextrans (Pharmaceutical Grade): These are precisely defined fractions produced by hydrolyzing native dextran and fractionating it to achieve narrow molecular weight distributions. The two most common pharmaceutical grades are dextran 40 (average molecular weight 40,000 Da) and dextran 70 (average molecular weight 70,000 Da). These are supplied as sterile solutions in saline or dextrose for intravenous administration.

· Dextran Derivatives: Chemical modification of dextran's abundant hydroxyl groups yields derivatives with specialized properties. Dextran sulfate incorporates sulfate esters, conferring negative charge and anticoagulant activity. Iron dextran is a stable complex of ferric oxyhydroxide with low-molecular-weight dextran, formulated for parenteral iron replacement therapy. Dextran polymers can also be crosslinked to form hydrogels or functionalized with targeting ligands for advanced drug delivery applications.

· Ophthalmic Dextran: Formulated as part of artificial tear solutions, typically containing dextran 70 at concentrations of 0.1 to 0.2 percent, combined with other lubricants like hypromellose or glycerol.

3. Common Supplemental Forms:

Dextran is not a dietary supplement in the conventional sense. It is a pharmaceutical agent and biomedical material, encountered in the following forms:

· Intravenous Solutions (Dextran 40, Dextran 70): Sterile, pyrogen-free solutions for volume expansion, hemodilution, and thromboembolism prophylaxis. These are prescription medications administered under medical supervision.

· Iron Dextran Injection: A parenteral iron formulation for treating iron deficiency anemia in patients who cannot tolerate or absorb oral iron. It carries a black box warning for anaphylactic reactions and requires a test dose before full administration.

· Ophthalmic Solutions: Over-the-counter artificial tear drops containing dextran 70 for symptomatic relief of dry eyes.

· Research-Grade Dextrans: Fluorescently labeled or functionalized dextrans of precisely defined molecular weights are used extensively in microcirculation studies, permeability assays, and as molecular weight markers for gel filtration chromatography.

· Dextran Hydrogels: Advanced wound dressings and drug delivery matrices, some of which are commercially available for specialized medical applications.

4. Natural Origin:

· Bacterial Source: Dextran is synthesized by specific strains of lactic acid bacteria, most notably Leuconostoc mesenteroides and Leuconostoc dextranicum. Certain Streptococcus and Lactobacillus species also produce dextrans.

· Biosynthesis: The process occurs extracellularly. The bacteria secrete the enzyme dextransucrase (also called glucansucrase) into the surrounding medium. This enzyme catalyzes the transfer of glucose units from sucrose to a growing dextran polymer chain, releasing fructose as a byproduct. The reaction can be represented as: n Sucrose → (Glucose)n + n Fructose. The resulting polymer's molecular weight and degree of branching are influenced by the specific bacterial strain and the reaction conditions.

· Precursors: The sole precursor for dextran synthesis is sucrose. The fructose liberated during the reaction is metabolized by the bacteria for energy.

5. Synthetic / Man-made:

· Process: Industrial production of dextran is a multi-step biotechnological process.

1. Fermentation: Leuconostoc mesenteroides is cultivated in large fermenters on a sucrose-rich medium under controlled conditions of pH, temperature, and aeration. Over 24 to 48 hours, the bacteria produce and secrete native, high-molecular-weight dextran.

2. Isolation and Purification: The fermentation broth is treated to kill the bacteria, which are then removed by centrifugation or filtration. The dextran is precipitated from the clear supernatant by adding a water-miscible organic solvent such as ethanol or methanol. The crude dextran is collected, washed, and dried.

3. Controlled Hydrolysis: The native dextran, with a molecular weight in the millions, is too large and polydisperse for clinical use. It is subjected to controlled acid hydrolysis, which randomly cleaves the polymer chains into smaller fragments.

4. Fractionation: The hydrolyzed mixture, containing a wide range of molecular weights, is then fractionated using differential ethanol precipitation or sophisticated membrane filtration techniques. This step isolates narrow molecular weight cuts, such as dextran 40 or dextran 70, with precisely defined specifications.

5. Formulation: The purified, fractionated dextran is dissolved in saline or dextrose solution, sterilized by autoclaving or filtration, and filled into sterile containers for clinical use.

6. Commercial Production:

· Precursors: Pharmaceutical-grade sucrose, bacterial strains of Leuconostoc mesenteroides, and solvents like ethanol.

· Process: The process described above is conducted in cGMP (current Good Manufacturing Practice) facilities to ensure sterility, purity, and consistent molecular weight distribution. Quality control involves rigorous testing for molecular weight (using techniques like size-exclusion chromatography), pyrogenicity, sterility, and heavy metals.

· Purity and Efficacy: Pharmaceutical dextrans meet strict pharmacopeial standards. Their efficacy as plasma expanders, antithrombotic agents, or iron carriers is directly linked to their defined molecular weight and narrow polydispersity. The 2025 StatPearls review confirms that dextran 40 and dextran 70 remain FDA-approved, though they have been largely replaced by safer alternatives in many clinical scenarios.

7. Key Considerations:

The Molecular Weight-Effect Relationship. The clinical behavior of dextran is exquisitely sensitive to its molecular weight. Dextran 70, with its larger molecules, is retained in the circulation for longer periods, making it an effective plasma volume expander. Dextran 40, with its smaller molecules, is rapidly excreted by the kidneys but exerts profound effects on microcirculatory flow by reducing blood viscosity and inhibiting erythrocyte and platelet aggregation. This molecular weight specificity means that different dextran fractions are not interchangeable; each is formulated for a specific therapeutic purpose. Furthermore, the clinical landscape has shifted. While dextrans were once frontline agents for volume resuscitation, they have been largely supplanted by crystalloids and albumin due to the risks of anaphylaxis, renal impairment, coagulopathy, and interference with blood crossmatching. Their use today is reserved for specialized scenarios, such as microsurgical procedures to improve flap perfusion, where their unique rheological benefits may outweigh the risks.

8. Structural Similarity:

Dextran belongs to the class of alpha-glucans, polysaccharides composed of glucose units. Its defining structural feature is the predominance of alpha-1,6 glycosidic linkages in the main chain, which gives the polymer significant flexibility and distinguishes it from other glucose polymers like starch (alpha-1,4 linked) and cellulose (beta-1,4 linked). The branches, typically one to two glucose units long, are attached via alpha-1,2, alpha-1,3, or alpha-1,4 linkages. The degree and type of branching vary with the producing bacterial strain and influence the polymer's solubility and biological interactions. Its molecular formula is represented generally as (C6H10O5)n, reflecting its polysaccharide nature.

9. Biofriendliness:

· Utilization: When administered intravenously, dextran remains within the vascular space initially, exerting its oncotic effect. Smaller molecules (below 50,000 Da, the renal threshold) are rapidly filtered by the kidneys and excreted unchanged in urine. Larger molecules are slowly taken up by the reticuloendothelial system (primarily in the liver and spleen), where they are metabolized to carbon dioxide and water over days to weeks. The rate of metabolism is slow because the alpha-1,6 linkages are resistant to human amylases, which target alpha-1,4 bonds.

· Distribution: Dextran's volume of distribution is initially confined to the intravascular space. Over time, some extravasation may occur, particularly in inflamed tissues with increased capillary permeability.

· Metabolism and Excretion: Molecules below the renal threshold are excreted rapidly in urine. Larger molecules are sequestered by the reticuloendothelial system and gradually metabolized. Approximately 70 mg per kilogram of body weight per day is metabolized to carbon dioxide and water.

· Toxicity: Dextran has low intrinsic toxicity. The primary risks associated with its use are immunological (anaphylaxis) and related to its effects on coagulation, renal function, and blood typing. The 2025 StatPearls monograph emphasizes that adverse effects are uncommon when administered appropriately but can be severe.

10. Known Benefits (Clinically Supported):

· Plasma Volume Expansion (Dextran 70): Rapidly restores circulating blood volume in hypovolemic shock from trauma, burns, or surgery. A 6 percent solution of dextran 70 is iso-oncotic with plasma and expands volume by approximately 120 percent of the infused volume for 12 to 24 hours.

· Microcirculatory Improvement (Dextran 40): Reduces blood viscosity and inhibits erythrocyte aggregation, improving flow through the microvasculature. This is utilized in vascular surgery, free flap transfers, and to prevent and treat thromboembolic disorders.

· Antithrombotic Effect: Both dextran 40 and 70 reduce platelet adhesiveness and aggregation by coating platelets and the vascular endothelium. They also reduce the activity of factor VIII and von Willebrand factor. This effect is dose-dependent and comparable to aspirin for venous thromboembolism prophylaxis, though rarely used for this indication alone today.

· Ophthalmic Lubrication: Dextran 70, combined with other agents in artificial tears, increases solution viscosity and residence time on the ocular surface, providing relief from dry eye symptoms and ocular irritation.

· Iron Replacement (Iron Dextran): Provides a parenteral source of iron for patients with iron deficiency anemia who cannot tolerate or absorb oral iron. The dextran stabilizes the ferric oxyhydroxide core, allowing for the administration of large, single-dose iron infusions.

· Diagnostic Imaging: Technetium-99m labeled dextran is used as a blood pool imaging agent for radionuclide ventriculography and the detection of pericardial effusions or ventricular aneurysms.

11. Purported Mechanisms:

· Colloid Osmotic Effect: Dextran molecules are too large to cross the vascular endothelium freely. Their presence in plasma increases the colloid osmotic pressure, which draws fluid from the interstitial space into the vascular compartment, expanding plasma volume.

· Coating and Charge Effect: Dextran adsorbs to the surfaces of platelets, erythrocytes, and the vascular endothelium. This coating reduces the surface charge and masks surface receptors involved in aggregation and adhesion, thereby inhibiting thrombus formation.

· Factor VIII and von Willebrand Factor Reduction: Dextran infusion reduces plasma levels of factor VIII and von Willebrand factor, key components of the coagulation cascade, contributing to its antithrombotic effect.

· Fibrin Polymer Modification: Dextran incorporates into forming fibrin clots, altering their structure to be more susceptible to fibrinolysis by plasmin.

· Volume of Distribution: In ophthalmic preparations, dextran's high molecular weight prevents its absorption across the conjunctiva, confining its lubricating action to the ocular surface.

12. Other Possible Benefits Under Research:

· Smart Wound Dressings: Dextran-based hydrogels are being developed as stimuli-responsive dressings for chronic wounds, particularly diabetic ulcers. These materials can be engineered to release antimicrobial or pro-healing agents in response to changes in pH, reactive oxygen species, or temperature at the wound site. A 2026 review in the Journal of Materials Science highlights the exceptional biocompatibility and tunable properties of these systems.

· Targeted Cancer Nanomedicine: Dextran conjugates are being investigated as carriers for targeted drug delivery. One promising approach, detailed in a 2025 PubMed study, uses dextran-based conjugates to deliver TLR7 agonists specifically to tumor-associated macrophages, converting them from a pro-tumor to an anti-tumor phenotype and enhancing the efficacy of chemotherapy.

· Iron Supplementation (Oral): Recent research from 2025 explores the development of oral iron dextran complexes using UV and hydrogen peroxide-degraded dextran. This approach aims to create a more stable and bioavailable oral iron supplement with high iron content and good thermal stability, showing promise in animal models of iron deficiency anemia.

· Drug Delivery Systems: Dextran hydrogels incorporating cyclodextrin microdomains are being studied for the sustained release of small-molecule drugs. Host-guest complexation between the drug and cyclodextrin within the hydrogel matrix can significantly prolong drug release, as demonstrated in 2023 research from A*STAR in Singapore.

· Dextran Sulfate in Research Models: Dextran sulfate sodium (DSS) administered in drinking water is the standard experimental model for inducing colitis in rodents, mimicking human ulcerative colitis. This model is invaluable for studying inflammatory bowel disease pathophysiology and testing potential therapies.

13. Side Effects:

· Allergic and Anaphylactoid Reactions: The most feared adverse effect. These range from mild skin rashes and urticaria to severe anaphylactic shock with hypotension, bronchospasm, and cardiac arrest. The incidence of severe reactions (grade III or higher) is estimated at 1 in 500 to 1 in 2000 administrations. These reactions are caused by preformed antibodies that cross-react with dextran.

· Hapten Prophylaxis: To mitigate this risk, the infusion of monovalent dextran 1 (Promit) as a hapten is mandatory before administering therapeutic dextrans. Dextran 1 (approximately 1000 Da) binds to the preformed antibodies without forming immune complexes that activate complement. It is infused 1 to 2 minutes before the therapeutic dextran.

· Coagulopathy and Bleeding: At doses exceeding 1.5 grams per kilogram per day, dextran can prolong bleeding time and increase the risk of surgical hemorrhage by its effects on platelet function and coagulation factors.

· Renal Impairment: Dextran 40, with its smaller molecules, can be filtered by the kidneys and, in high concentrations, increase urinary viscosity, leading to osmotic nephrosis and acute kidney injury, particularly in patients with pre-existing renal disease or dehydration.

· Interference with Blood Typing: Dextran can cause rouleaux formation (stacking of red blood cells), which interferes with blood crossmatching and typing. Blood samples should ideally be drawn before dextran administration.

· Volume Overload: Rapid or excessive infusion can precipitate pulmonary edema and congestive heart failure in susceptible patients, particularly those with cardiac dysfunction.

14. Dosing and How to Take:

· Dextran is a prescription medication and must be administered by qualified healthcare professionals. Dosing is highly individualized.

· For Hypovolemic Shock (Dextran 70): Typically 500 to 1000 mL of a 6 percent solution is infused intravenously at a rate appropriate to the patient's condition. The total dose should not exceed 20 mL per kilogram of body weight in the first 24 hours.

· For Microsurgical Prophylaxis (Dextran 40): A 10 percent solution is often infused at 20 to 40 mL per hour for several days post-operatively.

· Hapten Prophylaxis (Dextran 1): 20 mL (3 grams) is infused intravenously 1 to 2 minutes before the therapeutic dextran infusion.

· Ophthalmic Use: One to two drops in the affected eye(s) as needed for relief.

· Iron Dextran: A test dose (25 mg) is administered first, followed by observation for one hour. If no reaction occurs, the full therapeutic dose, calculated based on the patient's iron deficit, can be infused.

15. Tips to Optimize Benefits:

· In Clinical Settings:

· Hapten Prophylaxis is Non-Negotiable: Never administer therapeutic dextran without prior infusion of dextran 1.

· Adequate Hydration: Ensure the patient is well-hydrated before and during dextran infusion to minimize the risk of renal complications.

· Monitor Coagulation: Monitor for signs of bleeding and, if possible, obtain coagulation studies before administering high doses.

· Draw Blood Samples First: Collect blood for typing and crossmatching before starting the dextran infusion.

· In Research and Emerging Applications:

· Precise Molecular Weight Selection: For drug delivery or hydrogel applications, select dextran fractions with the precise molecular weight and polydispersity required for the desired degradation rate and release kinetics.

· Functionalization Strategy: The abundant hydroxyl groups on dextran offer multiple sites for chemical modification. Choose the appropriate chemistry (e.g., oxidation, esterification, click chemistry) based on the desired conjugation and crosslinking strategy.

16. Not to Exceed / Warning / Interactions:

· Absolute Contraindications: Known hypersensitivity to dextran, severe bleeding disorders, severe congestive heart failure, anuria, and severe dehydration.

· Drug Interactions:

· Anticoagulants and Antiplatelet Agents: Additive effects increase bleeding risk.

· ACE Inhibitors: Concurrent use with the dextran sulfate method for LDL apheresis is contraindicated due to the risk of bradykinin-mediated hypotension.

· Nephrotoxic Drugs: Concomitant use may increase the risk of renal impairment.

· Medical Conditions: Use with extreme caution in patients with asthma, epilepsy, or a history of allergic reactions. Dextran is relatively contraindicated in patients with pulmonary edema, renal insufficiency, or hepatic failure.

· Pregnancy and Lactation: Should only be used if clearly needed and the benefits outweigh the potential risks to the fetus or infant.

17. LD50 and Safety:

· Acute Toxicity (LD50): The LD50 in mice for intravenous dextran is approximately 2 to 4 grams per kilogram, indicating a wide margin between therapeutic and lethal doses for the compound itself.

· Human Safety: The primary safety concerns are not the intrinsic toxicity of the molecule but its immunological and physiological effects. Anaphylaxis, though rare, is a potentially fatal complication. Renal impairment and coagulopathy are dose-dependent and manageable with appropriate monitoring. The 2025 StatPearls review confirms that dextran is FDA-approved but emphasizes that it has been largely replaced by safer and more effective alternatives in most clinical settings.

18. Consumer Guidance:

· For Patients (Prescription Use): If you are receiving intravenous dextran, your healthcare team will monitor you closely for signs of allergic reaction (rash, itching, difficulty breathing), fluid overload, and bleeding. Report any unusual symptoms immediately.

· For OTC Ophthalmic Use: Dextran-containing artificial tears are safe for occasional use. If you experience eye pain, vision changes, or persistent irritation, discontinue use and consult an eye care professional.

· For Researchers: Dextrans are invaluable tools. Select products with certified molecular weights and low polydispersity for reproducible results. Be aware of the safety considerations when working with dextran sulfate or modified dextrans in biological systems.

· Label Literacy:

· Clinical Solutions: Labels will specify "Dextran 40" or "Dextran 70," the concentration (e.g., "6% in 0.9% Sodium Chloride"), and the total volume. The product monograph will contain full prescribing information, including the black box warning for anaphylaxis.

· Ophthalmic Solutions: Look for "Dextran 70" in the active ingredients section.

· Manage Expectations: Dextran is a powerful but potentially dangerous tool in modern medicine. Its role has evolved from a frontline volume expander to a specialized agent for specific clinical scenarios and a versatile platform for cutting-edge biomedical research. Its legacy endures not only in the protocols of transfusion medicine but also in the advanced hydrogels and nanomedicines that promise to shape the future of therapeutics.